Tatsis Ourania 4

What Happened
Ourania Tatsis, EVP & Chief Regulatory & Quality Officer at Vertex Pharmaceuticals (VRTX), disposed of a total of 1,887 shares valued at about $915,725. On 2026-02-24, 1,627 shares were surrendered to cover an exercise price or tax liability at $485.11 per share (value ~$789,274). On 2026-02-25, she sold 260 shares in an open-market sale at $486.35 per share (value ~$126,451). These were dispositions (sales/withholding), not purchases.

Key Details

• Transaction dates and prices:
  • 2026-02-24: 1,627 shares @ $485.11 — surrendered to cover exercise/tax liability (F) — ~$789,274
  • 2026-02-25: 260 shares @ $486.35 — open-market sale (S) — ~$126,451
• Total shares disposed: 1,887; total value ~ $915,725.
• Shares owned after the transactions: not specified in the provided filing.
• Footnote: Transactions made pursuant to a company-approved Rule 10b5-1 trading plan entered 08/21/2025.
• Filing: Form 4 filed 2026-02-26 covering the 02/24–02/25 trades; no late filing flag indicated in the provided information.

Context
Code F indicates shares were used to pay an exercise price or tax liability (commonly share-withholding after option exercise or vesting). The presence of a 10b5-1 plan (established 08/21/2025) means these trades were pre-authorized under a routine trading plan, which is designed to schedule transactions in advance and reduce questions about trading on inside information. Such dispositions are common for tax or liquidity needs and do not, by themselves, indicate the insider’s view of the company’s prospects.